Skip to main content
ChenDermatologist
ChenDermatologist
Dr. Chen Yi-Jia · Dermatology Notes
English version. Prefer Traditional Chinese? Switch to Chinese
Patient education · AD / Systemic Per AAD 2024 + 2023 + UpToDate 2024 Content updated 2026-10-16 · Physician reviewed 2026-05-09

Systemic therapy for atopic dermatitis
Biologics, JAK inhibitors, phototherapy compared

TL;DR:Systemic therapy comes after topical treatment fails to control the disease. Phototherapy is a reasonable alternative or bridge; biologics and JAK inhibitors differ in onset, administration and monitoring, and with Taiwan's reimbursement criteria the choice depends on severity and access.

When AD remains moderate-severe (EASI ≥ 16, IGA ≥ 3) or significantly impacts sleep/work after 4-8 weeks of adequate topical care, step up to systemic therapy. AAD 2024 update (Davis): (1) Biologics — dupilumab/Dupixent® (extensive long-term safety data), tralokinumab, lebrikizumab, nemolizumab (marked itch reduction in trials); (2) Oral JAK inhibitors — abrocitinib, upadacitinib (rapid onset, high clearance rates in trials, but FDA black-box warning); (3) NB-UVB phototherapy (alternative when biologics/JAKi unavailable). This article includes a detailed comparison chart.

Cover and reading information
In this article
  1. When to step up to systemic therapy
  2. Phototherapy
  3. Biologics (subcutaneous, extensive safety data)
  4. JAK inhibitors (oral, rapid onset, FDA black-box)
  5. Traditional immunosuppressants
  6. Decision framework
  7. Bottom line
Key Fact (Davis 2024, JAAD update · Davis 2024, JAAD photo+systemic)

Dupilumab launched the AD precision-medicine era in 2017. Before that, moderate-to-severe AD could only rely on cyclosporine (short-term) or struggle with topicals. Today 4 biologics + 3 JAK inhibitors achieve EASI 75 in 60–78% without routine blood monitoring. Taiwan NHI conditionally covers dupilumab, upadacitinib, abrocitinib and (from 2026/6/1) lebrikizumab for patients ≥ 12 years with EASI ≥ 16, inflamed BSA ≥ 30%, IGA 3–4 and prior phototherapy/systemic-treatment failure, after pre-authorization. Tralokinumab and nemolizumab are not NHI-covered for AD.

When to step up to systemic therapy

EASI ≥ 16 or IGA ≥ 3, BSA ≥ 10% with ≥ 3 nights/week sleep disturbance, DLQI ≥ 11 or POEM ≥ 17, or 4-8 weeks of adequate topical care without control.

Phototherapy

NB-UVB (311 nm) 2-3×/week × 12-24 weeks; EASI 50 ~ 50-60%. Pregnancy-safe. UVA1 for acute exudative AD (limited Taiwan availability). PUVA largely retired.

Biologics (subcutaneous, extensive safety data)

  • Dupilumab (anti-IL-4Rα): every 2 weeks SC, EASI 75 ~51%, ≥ 6 months age, FDA 2017, conjunctivitis 8-15%. Taiwan NHI-covered with criteria (age ≥ 12: EASI ≥ 16, inflamed BSA ≥ 30%, IGA 3–4, prior failures; separate criteria for ages 6 to under 12).
  • Tralokinumab (anti-IL-13): every 2 weeks SC, EASI 75 ~33%, ≥ 12 y.
  • Lebrikizumab (anti-IL-13, newer): every 4 weeks SC maintenance, EASI 75 ~53%, FDA 2024 ≥ 12 y. Taiwan NHI-covered with criteria from 2026/6/1 (≥ 12 y and ≥ 40 kg).
  • Nemolizumab (anti-IL-31R): every 4 weeks SC, itch reduction ~70%, EASI 75 ~36%, FDA 2024 ≥ 12 y.

JAK inhibitors (oral, rapid onset, FDA black-box)

  • Upadacitinib (JAK1) 15-30 mg/day, EASI 75 up to 78%, ≥ 12 y. Onset 1-2 weeks. Taiwan NHI-covered with criteria.
  • Abrocitinib (JAK1) 100-200 mg/day, EASI 75 ~60-73%, ≥ 12 y. Taiwan NHI-covered with criteria.
  • Baricitinib (JAK1/2): EU and Japan approved for AD; not FDA-approved for AD. EASI 75 ~25-30%.

Black-box: MACE, VTE, lymphoma, serious infections. Avoid age ≥ 65, smokers, prior CV/VTE/malignancy.

Traditional immunosuppressants

Cyclosporine 2.5-5 mg/kg/day (≤ 1 year, fast acting); methotrexate 10-25 mg/week; azathioprine 1-3 mg/kg/day (check TPMT); mycophenolate 2-3 g/day. Systemic steroids only as short-term bridge.

Decision framework

Higher clearance and oral preference → upadacitinib 30 mg. Long-term safety priority, no labs → dupilumab. Itch-dominant → nemolizumab. Failed dupilumab → lebrikizumab. Cannot use biologic/JAKi → NB-UVB + cyclosporine bridge.

Bottom line

Modern AD treatment offers 4 biologics + 3 JAKi reaching EASI 75 in 33-78% of patients. Dupilumab has extensive long-term safety data; upadacitinib offers rapid onset and high clearance rates in trials, with a black-box trade-off; nemolizumab uniquely targets itch. Discuss with your dermatologist based on goals, safety profile, convenience, and cost.